$2.90
-0.09[-3.01%]
At close: Apr 29
$2.90
0[0.00%]
After Hours: 4:00PM EDT
Reviva Pharmaceuticals
(NASDAQ:RVPH)Latest News for Reviva Pharmaceuticals Stock (NASDAQ:RVPH)
Reviva Pharmaceuticals Stock (NASDAQ: RVPH)
Categories: All
Monday, April 22, 2024
Tuesday, April 16, 2024
Monday, April 15, 2024
Thursday, March 28, 2024
Tuesday, March 26, 2024
- Reviva Pharmaceuticals Holdings shares are trading higher after the company announced that it will present RECOVER Phase 3 clinical trial data for brilaroxazine in schizophrenia at the ASCPT 2024 annual meeting.Benzinga Newsdesk - Mar 26, 2024, 12:23PM
- Reviva to Present RECOVER Phase 3 Clinical Trial Data For Brilaroxazine In Schizophrenia At The ASCPT 2024 Annual MeetingBenzinga Newsdesk - Mar 26, 2024, 8:12AM
Monday, March 25, 2024
Tuesday, February 20, 2024
Tuesday, February 06, 2024
Thursday, January 04, 2024
Tuesday, December 26, 2023
Friday, December 22, 2023
Monday, December 18, 2023
Thursday, November 16, 2023
Wednesday, November 15, 2023
Tuesday, November 14, 2023
Tuesday, October 31, 2023
Monday, October 30, 2023
- Analyst Assessment On Reviva Pharmaceuticals' Positive Schizophrenia Trial Data - Sees More Than 200% Upside In StockVandana Singh - Oct 30, 2023, 1:49PM
- 12 Health Care Stocks Moving In Monday's Intraday SessionBenzinga Insights - Oct 30, 2023, 1:30PM
- Roth MKM Reiterates Buy on Reviva Pharmaceuticals, Maintains $12 Price TargetBenzinga Newsdesk - Oct 30, 2023, 12:29PM
- Reviva Pharmaceuticals Holdings Shares Resume TradingBenzinga Newsdesk - Oct 30, 2023, 12:20PM
- Reviva Pharmaceuticals shares are trading higher after the company announced its pivotal Phase 3 RECOVER trial evaluating the efficacy, safety and tolerability successfully met its primary endpoint.Benzinga Newsdesk - Oct 30, 2023, 12:18PM
- Reviva Pharmaceuticals Shares Halted On Circuit Breaker To The Upside, Stock Now Up 80.3%Benzinga Newsdesk - Oct 30, 2023, 12:15PM
- Reviva Pharmaceuticals Shares Resume TradingBenzinga Newsdesk - Oct 30, 2023, 12:10PM
- Reviva Pharmaceuticals Shares Halted On Circuit Breaker To The Upside, Stock Now Up 45.1%Benzinga Newsdesk - Oct 30, 2023, 12:05PM
- Could This Be A Breakthrough in Mental Health? Reviva's Schizophrenia Drug Shows Promising Results In Key TrialVandana Singh - Oct 30, 2023, 11:45AM
- Reviva Pharmaceuticals Shares Resume TradeBenzinga Newsdesk - Oct 30, 2023, 9:38AM
- 12 Health Care Stocks Moving In Monday's Pre-Market SessionBenzinga Insights - Oct 30, 2023, 9:05AM
- Reviva Pharmaceuticals' Phase 3 RECOVER Trial Of Once-daily Brilaroxazine For Schizophrenia Met Its Primary Endpoint, With 50 mg Brilaroxazine Dose Achieving A Statistically Significant And Clinically Meaningful Reduction In Positive And Negative SyndromeBenzinga Newsdesk - Oct 30, 2023, 7:34AM
Friday, October 27, 2023
Monday, September 25, 2023
Wednesday, September 20, 2023
Thursday, August 17, 2023
Wednesday, August 16, 2023
Monday, August 14, 2023
Tuesday, July 11, 2023
Monday, June 26, 2023
- Expert Ratings for Reviva PharmaceuticalsBenzinga Insights - Jun 26, 2023, 9:00AM
- HC Wainwright & Co. Reiterates Buy on Reviva Pharmaceuticals, Maintains $10 Price TargetBenzinga Newsdesk - Jun 26, 2023, 6:17AM
- Reviva Pharmaceuticals To Be Added To Russell Microcap IndexBenzinga Newsdesk - Jun 26, 2023, 6:03AM
Thursday, June 22, 2023
Thursday, June 08, 2023
- Benzinga's Top Ratings Upgrades, Downgrades For June 8, 2023Benzinga Insights - Jun 8, 2023, 11:00AM
- Where Reviva Pharmaceuticals Stands With AnalystsBenzinga Insights - Jun 8, 2023, 9:02AM
- Benchmark Initiates Coverage On Reviva Pharmaceuticals with Speculative Buy Rating, Announces Price Target of $17Benzinga Newsdesk - Jun 8, 2023, 8:46AM